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ABSTRACT 
The purpose of the present work was to develop new, 
simple, specific, accurate and precise stability indicating RP-HPLC 
method for determination of ceritinib. In the present study, 
stress testing of ceritinib was carried out according to ICH 
guidelines Q1A (R2). ceritinib was subjected to stress conditions 
of hydrolysis, oxidation, photolysis and neutral decomposition. 
Extensive degradation was found to occur in acidic condition. Mild 
degradation was observed in basic and at thermal conditions. 
Successful separation of drug from degradation products formed 
under stress conditions was achieved on a Hypersil BDS C18 
column (250×4.6mm, 5.0μ particle size) using acetonitrile: 
acetate buffer (pH 3.7±0.05) (50:50 v/v), at a flow rate of 
1.0mL/min and column was maintained at 40°C. Quantification 
and linearity were achieved at 272nm over the concentration 
range of 5-100μg/mL for ceritinib. The Correlation Coefficient 
was found to be 0.9960. The method was validated for 
specificity, linearity, accuracy, precision, LOD, LOQ and 
robustness. The developed method will be useful for routine 
analysis for samples of stability studies in the formulation and 
development.  
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INTRODUCTION 
Ceritinib, 5-Chloro-N4-[2-[(1-
methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-
(1-methyl-ethoxy)-4-(4-piperidinyl)phenyl] 2,4-
pyrimidine diamine, is an anaplastic lymphoma 
kinase (ALK) inhibitor which induces complete 
tumor regression in a xenograft model of 
EML4-ALK-positive lung cancer. The 
alternative names of ceritinib are LDK 378, 
NVP-LDK 378, ZykadiaTM. Ceritinib is a 
highly selective inhibitor of an important cancer 
target, ALK (Heudi, et. al., 2014). Ceritinib, a 
recently approved drug by Food and Drug 
Administration, is used for the treatment of 
late-stage (metastatic) non-small cell lung 
cancer (Waters, 2014). The recommended 
dosage of ceritinib is 750 mg administered 
orally once daily on an empty stomach (Shaw, et 
al., 2014). The chemical structure of ceritinib 
(Figure 1). 
An ultrafast, sensitive, selective, and 
robust LDTD-APCI-MS/MS method was 
developed for the quantification of ceritinib      
in  human plasma (Lanshoeft, 2015). A stability  
 
 
 
Figure 1. Structure of Ceritinib 
 
indicating reversed-phase high-performance 
liquid chromatographic (RP-HPLC) method for 
estimation of ceritinib was reported (Kumar., 
2014). Since, there are only two HPLC method 
reported in the literature for the estimation of 
ceritinib in pharmaceutical dosage forms 
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(Chintala, et al., 2015), (Reddy, et al., 2016 ), 
therefore, there is a need to develop 
quantitative methods under different conditions 
to achieve improvement in sensitivity, 
selectivity, as per ICH guidelines (2005). The 
developed method will be novel for             
Stability studies and use in the routine analysis 
for samples in stability study which was very 
important part of formulation and development.  
 
MATERIAL AND METHODS 
Reagents and materials 
Ceritinib (purity > 99%) procured from 
Spectrum lab, Hyderabad, India was used for 
the study. All the chemicals used of HPLC 
Grade (MERCK. Chem. Ltd., Mumbai) and 
HPLC grade water was used for mobile phase 
preparation. Nylon membrane filter 0.45µ 
syringe filter. Hydrogen peroxide, sodium 
hydroxide and hydrochloric acid are used of 
AR grade. 
 
Chromatographic conditions: 
The chromatographic separation was 
achieved on Perkin Elmer (USA) HPLC system 
(series 200) equipped with Perkin Elmer series 
200 pump system having back pressure 5000 
psi, manual injector of 20μL loop, UV-Visible 
detector and Hypersil BDS C18 column 
(250mm x 4.6mm i.d., 5µm); Sartorious, 
analytical balance; An ultra-sonicator; A 
Shimadzu model 1800 double beam UV/Vis. 
spectrophotometer with a pair of 10mm matched 
quartz cells. The mobile phase comprised of 
acetonitrile: acetate buffer (pH 3.7±0.05) 
(60:40% v/v), at a flow rate of 1.0mL/min, and 
column was maintained at 40°C. The mobile 
phase was filtered through nylon 0.45 µm 
membrane filter and was degassed before being 
used for analysis. The UV-Visible detector was 
set at 272nm. The injection volume was 20µL 
and total run time was 10min.  
 
Preparation of the mobile phase 
The mobile phase was prepared by 
mixing 60mL acetonitrile and 40mL acetate 
buffer (pH 3.7±0.05) previously filtered 
through 0.45µm nylon membrane filter. The 
mobile phase was degassed for 15min by 
sonicating the solution before use. 
 
 
Preparation of Diluent 
Acetonitrile: Water (60:40% v/v) was 
used as diluent. 
Preparation of standard solution 
Accurately weighed ceritinib (25mg) was 
transferred to a 25mL volumetric flask, 
dissolved in and diluted to the mark with 
diluent to obtain a standard stock solution 
(1mg/mL). 
 
Preparation of working standard 
solution (10µg/mL) 
Standard solution (0.1mL) was 
transferred in a 10 mL volumetric flask and 
diluted up to the mark with mobile phase. 
 
Analysis of tablet dosage form 
Twenty tablets (ZYKADIA) were 
weighed and average weight was calculated. 
The tablets were finely powdered, and a quantity 
of powder equivalent to 25mg ceritinib was 
weighed accurately and transferred to a 25mL 
volumetric flask containing 15mL diluent, and 
sonicated for 15min. The solution was allowed 
to stand at room temperature for 5min and the 
volume was made up to the mark with           
diluent to obtain the sample stock solution 
(1mg/mL). The solution was filtered through 
0.45µ membrane filter. Aliquot (1.0mL) was 
taken and transferred to 10mL volumetric flask 
and volume was made up to the mark              
with diluent to give a solution containing 
100µg/mL ceritinib. The solution (2.0mL) was 
transferred to 10 mL volumetric flask and 
diluted up to the mark with mobile phase              
to give a solution containing 20µg/mL 
ceritinib. An aliquot (20µL) was injected               
and the chromatogram was recorded. The            
peak area was noted and the amount of 
ceritinib was calculated from the regression 
equation. 
 
Forced degradation study 
Ceritinib was subjected to various forced 
degradation conditions to affect partial 
degradation of the drug preferably in 20-80% 
range. The study provided information about 
the conditions in which the drug was unstable. 
This Information was useful for development 
of formulation. 
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Effect of acid, alkaline and neutral hydrolysis 
Accurately weighed ceritinib 25mg was 
transferred to three different 100mL volumetric 
flasks and dissolved in diluent (20mL). 
Hydrochloric acid (0.1N, 10mL), sodium 
hydroxide (0.1N, 10mL) and water (10mL) 
were added to separate flasks containing drug 
samples and mixed properly for acidic, alkaline 
and neutral degradation respectively and stored 
at room temperature for 72h. 
The samples were neutralized with base 
or acid as appropriate and diluted up to the 
marks with diluent to obtain stock solutions 
(250µg/mL). Dilutions were made with mobile 
phase to obtain the degraded ceritinib solutions 
(25µg/mL). 
 
Effect of oxidation 
Accurately weighed ceritinib 25 mg was 
transferred to a 100mL volumetric flask and 
dissolved in diluent 20mL. Hydrogen peroxide 
solution (3%) 10mL was added, mixed, and 
stored at room temperature for 72h. The 
sample was diluted up to the mark with 
acetonitrile to obtain stock solution (250µg/mL). 
Dilution was made with mobile phase to obtain 
the degraded Ceritinib solution (25µg/mL). 
 
Effect of heat 
Ceritinib 25mg was distributed over a 
glass plate and kept in an oven at 60°C for 72h, 
then ceritinib was transferred in a 100mL 
volumetric flask, and dilutions were made with 
mobile phase to obtain the degraded ceritinib 
solution (25µg/mL). 
 
Effect of light 
Ceritinib solution (prepared by 
dissolving 25mg ceritinib in 20mL acetonitrile 
in 100mL volumetric flask) was exposed to sun 
light for 48h, while ceritinib powder 25mg was 
exposed to UV light for 48h. After exposure, 
dilutions were made to obtain the degraded 
ceritinib solutions (25µg/mL). Aliquots               
(20µL) of the stressed samples were injected 
into the HPLC system as described under 
chromatographic conditions and the chromate-
grams were recorded. 
 
Method validation 
As per the ICH guideline Q2 (R1) 
(2005), the method validation parameters 
namely specificity, linearity, accuracy, precision, 
limit of detection, limit of quantitation and 
robustness were studied. 
 
Solution stability 
Sample solutions were kept at 25±2°C 
(24h) and 2-8°C (3 days), respectively.             
Assay percentage of initial time period              
was compared with these two time periods.                
The change in the assay percentage was 
calculated. The difference between assay results 
should not be more than 2% for formulation, 
and 0.5% for active pharmaceutical ingredient 
(API). 
 
Specificity 
Chromatograms of ceritinib solutions 
and degraded samples were studied in order to 
provide an indication of the stability indicating 
properties and specificity of the method. The 
stress conditions employed were acidic, 
alkaline, neutral, oxidative, thermal and 
photolytic degradation. The degraded samples 
were analyzed against freshly prepared sample 
solutions. 
 
Linearity (Calibration Curve) 
Standard solutions (0.05, 0.1, 0.15, 0.2, 
0.25 and 0.3mL equivalent to 5.0, 10.0, 15.0, 
20.0, 25.0 and 30.0µg/mL of ceritinib) were 
transferred in a series of 10mL volumetric 
flasks and diluted to the mark with mobile 
phase. An aliquot (20µL) of each solution was 
injected under the operating chromatographic 
conditions as described earlier. Calibration 
curve was constructed by plotting peak areas 
versus concentrations, and the regression 
equation was calculated. Each response was 
average of three determinations. 
 
 Accuracy (% recovery) 
Accuracy of the method was determined 
by calculating percentage recovery of ceritinib 
by the standard addition method. Known 
amount of standard solutions of ceritinib (0, 5, 
10 and 15µg/mL) were added to a pre-analyzed 
sample solution of ceritinib (10µg/mL). Each 
solution was injected in triplicate, and the 
percentage recovery was calculated by 
measuring the peak areas and fitting these 
values into the regression equation of the 
calibration curve. 
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Precision 
Repeatability was checked by repeatedly 
(n = 6) injecting ceritinib solution (10 µg/mL) 
and recording the chromatogram. Intra-day and 
inter-day precisions of the developed method 
was determined by measuring the 
corresponding responses 3 times on the same 
day and on 3 different days over a period of 1 
week for 3 different concentration of ceritinib 
(10.0, 20.0 and 30.0µg/mL). The results were 
reported in terms of relative standard deviation. 
 
Limit of detection and limit of quantification 
Limit of detection (LOD) and the limit 
of quantification (LOQ) were calculated using 
the standard deviation of response (σ) and 
slope (S) of the calibration curve. 
LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
 
Robustness 
Robustness was studied by analyzing the 
samples of ceritinib by deliberate variation in 
the method parameters. The change in the 
response of ceritinib was noted. Robustness of 
the method was studied by changing the 
extraction time of ceritinib from tablet dosage 
form by ±2 min, composition of mobile phase 
by ±2% of organic solvent, wavelength by ±2 
nm, flow rate by ±0.2 mL/min and column 
oven temperature by  2ºC. The changes in the 
response of ceritinib were noted and compared 
with the original one. 
 
System-suitability test 
System suitability tests were used to 
verify that the resolution and repeatability of 
the system were adequate for the analysis 
intended. The parameters used in this test were 
retention time, tailing factor and theoretical 
plates of chromatographic peak as RSD of peak 
area for replicate injections. 
 
RESULTS AND DISCUSSION 
Selection of column and mobile phase 
As per the published literature and 
knowledge of the molecule, reverse phase liquid 
chromatography (RP-HPLC) is suitable for 
analysis of ceritinib. In case of RP-HPLC 
various columns are available, but as the              
main         aim   of   the  method  was to resolve the   
  
compound from degraded products, C18 
column (250x4.6mm i.d., 5µm particle size) was 
preferred over the other columns. Resolution is 
the most important criteria for the method, it is 
imperative to achieve good resolution among 
the compound and degraded products. As per 
the value of pKa and solubility of compound 
various composition of mobile phase were 
tried. 
The chromatographic conditions were 
optimized with a view to develop a stability 
indicating assay method, which can separate the 
drug from its degradation products with good 
resolution. Mobile phase consisting of 
acetonitrile: acetate buffer (pH 3.7±0.05) 
(50:50% v/v) at a flow rate of 1.0mL/min, was 
found to be satisfactory to obtain well-resolved 
peaks with better reproducibility and 
repeatability for ceritinib (Figure 2). 
 
 
Method validation 
The change in assay results after storage 
at 25°C (24h) and 2-8°C (3 days) was evaluated. 
It was found that the difference in assay results 
was not more than 2% for formulation, and 
0.5% for API, indicating stability of ceritinib 
solution. 
The developed analytical method was 
found to be specific as there was no inference 
of any related impurities after the stress 
degradation study (Figure 3). It was shown that 
the ceritinib peaks were free from excipients 
and co-eluting impurities. 
The linear correlation was obtained 
between peak area and concentration of 
ceritinib in the range of 5-30µg/mL, the 
linearity of the calibration curve was validated 
by the value of correlation coefficient of the 
regression (r) and the Y intercept were found to 
be 0.9960 and Y =38217x+72833 respectively. 
The regression analysis of the calibration curves 
(Table I). 
The accuracy study was carried out by 
the standard addition method at level of ±50 % 
of standard concentration. The percent 
recoveries were found in the range of 98.86-
101.12%, which indicated accuracy of the 
method (Table II). The accuracy study had 
shown results within the limit of % RSD less 
than 2%. 
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The % RSD for repeatability (Table III) 
of ceritinib was found to be 1.25. The value of 
% RSD for intra-day precision was found to be 
in the range of 0.93 - 1.15% and inter-day 
precision was found to be in the range of 1.07 - 
1.22 %, which indicated that the method was 
precise (Table IV). The Precision study showed 
results within the limit of % RSD less than 2%. 
The Limit of detection (LOD) for ceritinib was 
found to be 0.062µg/mL, while the Limit of 
quantification (LOQ) was 0.187µg/mL. The 
method was found to be robust as the results 
were not significantly affected by slight 
variation in extraction time, composition of 
mobile phase, wavelength and flow rate of the 
mobile phase. 
System-suitability test 
The % RSD of retention time,            
tailing factor, and theoretical plates were             
found to be 1.26%, 1.08% and 0.46% 
respectively. The% RSD of system-suitability 
test parameters was found satisfactory as                          
% RSD should not be more than 2%             
(Table V). 
 
Analysis of tablet dosage form 
The proposed RP-HPLC method                
was successfully applied for determination              
of ceritinib from tablet dosage form.                   
The percentage of ceritinib was found to be 
99.07%; which was comparable with the 
corresponding label claim (Table VI). 
 
 
Figure 2. Chromatogram of ceritinib with retention time of 4.41min 
 
 
 
 
Figure 3. Calibration curve of ceritinib 
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Degradation study 
Forced degradation study of ceritinib 
was carried out under various stress conditions 
as follows 
 
Effect of acid, alkaline and neutral 
hydrolysis 
Ceritinib was found to undergo 64.67% 
decomposition under acidic stress condition 
with a major degradation product at retention 
time of about 3.88 min and minor degradation 
product   at   retention   time of    about  2.30min  
and minute decomposition about 3.7% under 
basic stress condition with a degradation product 
at retention time of about 2.30min. Under 
neutral degradation condition, no degradation 
was observed. Hence, ceritinib was found to be 
highly degradable in basic condition, and very 
minute degradable in acidic condition but not 
degradable in neutral condition. 
 
Effect of oxidation 
In oxidation stress condition, almost 
9.5% of ceritinib was degraded and degradation 
peak appeared in chromatogram at 2.30min 
retention time.  
 
Effect of heat 
Under dry thermal stress condition, 
ceritinib was degraded about 12.23% with 
degradation product at retention time of about 
2.58 and 6.83min. 
 
Effect of light 
When ceritinib in solution state was 
exposed  to  sun  light;  and ceritinib in powder  
state was exposed to UV light, no degradation 
was observed, respectively. 
  
Table I. Optical and regression characteristics (n=3) 
 
Parameter Ceritinib 
Linearity range (µg/mL) 5-30 
Linearity equation y = 38217x+72833 
LOD (µg/mL) 0.062 
LOQ (µg/mL) 0.187 
Correlation coefficient (r) 0.9960 
 
Table II. Results of recovery study (n=3) 
 
Amount 
Taken (µg/mL) 
Amount 
added (µg/mL) 
Amount 
Found (µg/mL) 
Recovery  
± S.D, % 
%  
RSD 
10 0 10.05 100.50±0.92 0.92 
10 5 14.83 98.86±1.65 1.65 
10 10 19.90 99.50±1.37 1.37 
10 15 25.28 101.12±0.77 0.77 
 
Table III. Results of repeatability (n=6) 
 
Drug 1 2 3 4 5 6 Mean SD % RSD 
Ceritinib 
443614.0 454953.1 443275.4 445228.7 448743.8 438564.2 445729.9 5590.19 1.25 
Peak area 
 
Table IV. Results of Intra-day and Inter-day precision (n=3) 
 
Ceritinib 
(µg/mL) 
Intra-day precision Inter-day precision 
Mean peak area ± SD % RSD Mean peak area ± SD % RSD 
10 443614.0±4152.12 0.91 448745.3±4836.18 1.04 
20 875777.0±9638.35 1.08 878418.6±9858.21 1.07 
30 1200410.0±13864.16 1.13 1201059.6±14728.26 1.12 
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The samples exposed to acidic, alkaline, 
neutral, oxidative, thermal and photolytic 
conditions were colorless. In Photolytic 
stability, ceritinib was found to be stable 
showing no degradation. All degradates were 
resolved from ceritinib peak and the percentage 
degradation for each condition indicated that 
there was no interference from degradates in 
determination of the ceritinib in tablet dosage 
form. Thus, the proposed, method was found 
to be "Stability Indicating". 
 
CONCLUSION 
An isocratic stability indicating reverse 
phase liquid chromatographic method has been 
developed and validated for the estimation of 
ceritinib in tablet dosage form, the method was 
found to be specific as there was no 
interference of any co-eluting impurities after 
stress degradation study. The proposed method 
was found to be simple, accurate, precise, 
sensitive and robust. Hence, it can be used 
successfully for the routine analysis of ceritinib 
in pharmaceutical dosage forms, and for 
analysis of stability samples obtained during 
accelerated stability study 
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